Development PipelineSEA-CD70

an investigational sugar-engineered antibody directed to CD70

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

SGNS70-101: Myelodysplastic syndrome and acute myeloid leukemia

  • Phase 1

  • Phase 2

  • Phase 3

Program Resources

High-level synopsis of SEA-CD70 and ongoing clinical trials

Detailed information about SEA-CD70 clinical trials